AbCellera Biologics (ABCL) Operating Margin (2020 - 2026)
AbCellera Biologics (ABCL) reported Operating Margin of 691.75% for Q1 2026, up 78783.0% on a YoY basis from N/an in Q1 2025, and down 985.55% quarter-over-quarter from 63.72% in Q4 2025.
AbCellera Biologics (ABCL) Operating Margin (2020 - 2026) Analysis & Trends
AbCellera Biologics has reported Operating Margin for 7 years, with the latest figure at 691.75% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin rose 78783.0% year-over-year to 691.75%; the trailing twelve-month figure through Mar 2026 stood at 267.61% (up 112773.0% YoY), and the FY2025 full-year result was 288.98%, up 80271.0% from the prior year.
- Operating Margin for Q1 2026 stood at 691.75%, down from 63.72% in the prior quarter.
- The five-year high for Operating Margin was 71.06% in Q1 2022, with the low at 1479.57% in Q1 2025.
- Historically, Operating Margin has averaged 633.22% across 5 years, with a median of 551.48% in 2024.
- The largest YoY upside for Operating Margin was 137697 bps in 2025 against a maximum downside of 92810 bps in 2025.
- AbCellera Biologics' Operating Margin stood at 175.34% in 2022, then tumbled by 310 bps to 719.61% in 2023, then sank by 100 bps to 1440.69% in 2024, then jumped by 96 bps to 63.72% in 2025, then sank by 986 bps to 691.75% in 2026.
- The last three Operating Margin figures came in at 691.75% (Q1 2026), 63.72% (Q4 2025), and 851.79% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | AbCellera Biologics | 1.55 Bn | 1.44 Bn | - | -691.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -691.75% |
| Dec 31, 2025 | -63.72% |
| Sep 30, 2025 | -851.79% |
| Jun 30, 2025 | -290.24% |
| Mar 31, 2025 | -1,479.57% |
| Dec 31, 2024 | -1,440.69% |
| Sep 30, 2024 | -1,439.42% |
| Jun 30, 2024 | -1,276.17% |
| Mar 31, 2024 | -551.48% |
| Dec 31, 2023 | -719.61% |
| Sep 30, 2023 | -831.79% |
| Jun 30, 2023 | -511.03% |
| Mar 31, 2023 | -532.10% |
| Dec 31, 2022 | -175.34% |
| Sep 30, 2022 | 37.22% |
| Jun 30, 2022 | -18.29% |
| Mar 31, 2022 | 71.06% |
| Dec 31, 2021 | 58.53% |
| Sep 30, 2021 | -510.09% |
| Jun 30, 2021 | -25.44% |